Thursday 4 June 2020 ,
Thursday 4 June 2020 ,
Latest News
  • Killing of 26 Bangladeshis: 'Mastermind' killed in drone attack
  • Passenger shortage forces Biman to cancel flights
  • 5 die in Chandpur hospital isolation ward in 24hr
  • Sell TCB goods at Upazila, municipality levels: HC
  • Bangladesh records 2695 coronavirus cases, 37 deaths in 24 hrs
  • Coronavirus Hotline Numbers: 01944333222, 16263, 333; website: www.corona.gov.bd
16 April, 2019 00:00 00 AM

Recurrence score may cut costs for high-risk breast cancer care

drugs.com
Recurrence score may cut costs for high-risk breast cancer care

Genomic recurrence score (RS) testing using a 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy, according to a study published in the March issue of the Journal of the National Comprehensive Cancer Network.

Michaela A. Dinan, Ph.D., from the Duke University School of Medicine in Durham, North Carolina, and colleagues used SEER-Medicare data to identify a nationally representative sample of 30,058 Medicare beneficiaries diagnosed with early-stage, estrogen receptor-positive breast cancer from 2005 through 2011. Associations between RS testing and overall and chemotherapy-specific costs were evaluated.

The researchers found that 17.5 percent of patients received RS testing; of these, 13.3 percent were initially clinically classified as low-risk, 69.5 percent as intermediate-risk, and 17.2 percent as high-risk. One year after diagnosis, mean costs were $35,940 overall, $51,127 for clinically high-risk disease, $33,225 for intermediate-risk disease, and $26,695 for low-risk disease. Similar trends were seen for chemotherapy-specific costs.

RS testing was associated with significantly lower costs among high-risk patients for both relative costs (cost ratio, 0.88) and absolute costs ($6,606). In low-risk and intermediate-risk patients, higher costs were mainly caused by higher noncancer costs. In analyses of all 64,996 patients aged ≥66 years, associations between RS testing and costs among high-risk patients were similar but less marked because of lower overall use of chemotherapy.

"In the big picture, the ability for RS testing to reduce either the cost of chemotherapy or total health costs may depend on the general distribution of patients who are clinically considered to be high-, intermediate-, or low-risk," Dinan said in a statement.

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Tuberculosis is an age old disease and first spread probably 8000 years back. Killer T.B was described in India 3000 B.C. Mummified bodies of Egypt have…
World Tuberculosis Day 2020

World Tuberculosis Day 2020

Each year, we commemorate World Tuberculosis (TB) Day on March 24 to raise public awareness about the devastating health, social and economic consequences…
Tuberculosis (TB): Symptoms, causes & treatment

Tuberculosis (TB): Symptoms, causes & treatment

What is Tuberculosis? Tuberculosis -- or TB, as it’s commonly called -- is a contagious infection that usually attacks your lungs. It can spread…
WHO on Tuberculosis

WHO on Tuberculosis

Key facts •    A total of 1.5 million people died from TB in 2018 (including 251 000 people with HIV). Worldwide, TB is one of the…
Hearing loss screening for patients with TB and diabetes urged

Hearing loss screening for patients with TB and diabetes urged

MUHAMAMD ZAHIR HASSAN NABIL On this World Tuberculosis Day, Bangladesh remains one of 30 high TB and MDR-TB burden countries with 221 people affected…
Autism rates declining among wealthy whites, escalating among poor

Autism rates declining among wealthy whites, escalating among poor

Wealthy, white California counties—once considered the nation's hotbeds for autism spectrum disorder (ASD) - have seen prevalence flatten or…
What is Coronavirus (COVID-19)?

What is Coronavirus (COVID-19)?

COLLEEN DOHERTY, MD   The 2019 Novel Coronavirus (COVID-19) Outbreak COVID-19 is a new type of coronavirus, a common family of viruses, which surfaced…
Coronavirus patients, doctors seem to be temporarily losing their sense of taste and smell — here’s why

Coronavirus patients, doctors seem to be temporarily losing their sense of taste and smell — here’s why

ABBY HAGLAGE Healthcare workers wait for people to arrive at a COVID-19 mobile testing site in Florida. New reports from the UK show that both doctors…
10 common health conditions that may increase risk of death from the coronavirus, including diabetes and heart disease

10 common health conditions that may increase risk of death from the coronavirus, including diabetes and heart disease

According to a report on patient characteristics from Italy's National Institute of Health released on March 17, 99% of COVID-19 patients who have…
Coronavirus: Doctors urge conversations about dying

Coronavirus: Doctors urge conversations about dying

DR FAYE KIRKLAND Palliative care doctors are urging people to have a conversation about what they would want if they, or their loved ones, became seriously…
What does a self-quarantine look like?

What does a self-quarantine look like?

Many peoples are choosing -- or have been told -- to self-quarantine to slow the spread of COVID-19. Doctors at the University of Texas Health Science…
ACE inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

ACE inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

James Diaz, MD, MHA, MPH & TM, Dr. PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has…
FDA approves Nurtec ODT (rimegepant) for the acute treatment of migraine in adults

FDA approves Nurtec ODT (rimegepant) for the acute treatment of migraine in adults

Biohaven Pharmaceutical Holding Company Ltd. recently announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant)…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting